Skip to main content

Table 1 Baseline patient characteristics of different degrees of ST-segment resolution

From: ST-segment resolution as a marker for severe myocardial fibrosis in ST-segment elevation myocardial infarction

Variables All (n = 42) ST-segment resolution ≥ 40.15% ST-segment resolution < 40.15% P
(n = 26) (n = 16)
Male/female (n) 30/12 20/6 10/6 0.483
Age (years) 62.0 (54.5–70.0) 60.5 (52.8–70.3) 63.5 (59.5–69.5) 0.534
BMI (Kg/m2) 24.2 (23.0–25.6) 24.3 (23.4–25.8) 24.2 (21.9–24.7) 0.378
Smoking history (No, %) 27 (64.3%) 17 (65.4%) 10 (62.5%) 0.850
HP history (no, %) 27 (64.3%) 14 (53.8%) 13 (81.2%) 0.072
DM history (no, %) 16 (38.1%) 12 (46.2%) 4 (25.0%) 0.170
Hyperlipidemia (no, %) 21 (50.0%) 13 (50.0%) 8 (8.0%) 1.000
Pain to balloon time (h) 5.79 (3.67–7.60) 4.33 (3.50–6.23) 7.04 (5.81–8.40) * 0.001
Killip classification (no, %)     0.757
 Killip I 29 (74.4%) 19 (79.2%) 10 (66.67%)  
 Killip II 10 (25.6%) 5 (20.8%) 5 (33.33%)  
Number of DES (no, %)     0.142
 One 34 (87.2%) 22 (95.7%) 12 (75.0%)  
 Two 3 (7.7%) 1 (4.3%) 2 (12.5%)  
 Three 2 (5.1%) 0 (0.0%) 2 (12.5%)  
Culprit artery, (No, %)     0.171
 LAD 18 (42.9%) 8 (30.8%) 10 (62.5%)  
 LCC 11 (26.2%) 8 (30.8%) 3 (18.8%)  
 RCA 13 (31.0%) 10 (38.5%) 3 (18.8%)  
WBC count (109/L) 9.85 (8.28–12.06) 10.09 (8.28–12.06) 9.72 (8.03–14.12) 0.875
RBC count (1012/L) 4.44 (3.91–4.82) 4.44 (4.14–4.86) 4.45 (3.71–4.72) 0.449
Hb (g/L) 139.0 (125.0–151.0) 139.0 (128.0–151.0) 135.5 (113.3–150.8) 0.449
PLT (109/L) 198.0 (163.0–238.0) 195.0 (160.0–213.0) 212.5 (175.0–282.3) 0.204
HbA1c (%) 6.0 (5.7–7.2) 6.1 (5.7–8.2) 5.9 (5.7–6.4) 0.188
ALT (U/L) 42.0 (35.0–56.0) 41.0 (35.0–56.0) 46.0 (36.0–53.5) 0.689
AST (U/L) 126.0 (52.0–209.0) 75.0 (35.0–153.0) 185.5 (101.1–237.3) 0.015
Cr (umol/L) 73.0 (60.0–81.0) 73.0 (59.0–81.0) 71.5 (60.3–83.3) 0.954
BNP (pg/ml) 57.9 (7.9–245.0) 11.7 (5.0–62.7) 227.5 (80.0–381.2) * < 0.001
Peak troponin-T (ng/ml) 11.6 (6.2–19.3) 7.0 (3.8–14.0) 18.6 (12.2–24.9) * < 0.001
LVIDd (mm) 49.0 ± 3.3 49.0 ± 3.3 49.5 ± 3.2 0.298
LVEF (%) 53.5 (48.0–58.25) 57.0 (53.5–61.0) 47.5 (44.3–50.0) * < 0.001
Scar thickness 70.0 (55.0–80.0) 59.0 (50.0–70.0) 81.0 (80.0–85.0) * < 0.001
Transmural myocardial scar (no, %) 17 (40.5%) 2 (7.7%) 15 (93.8%)* < 0.001
Scar size 17.35 (12.23–20.30) 12.90 (11.13–19.40) 20.00 (18.13–23.63) * 0.001
IIa/IIIb inhibitor (no, %) 17 (43.6%) 11 (47.8%) 6 (37.5%) 0.522
Aspirin (no, %) 39 (100.0%) 23 (100.0%) 16 (100.0%) 1.000
Ticagrelor/clopidogrel (no, %) 39 (100.0%) 23 (100.0%) 16 (100.0%) 1.000
Statins (no, %) 39 (100.0%) 23 (100.0%) 16 (100.0%) 1.000
β-blocker (no, %) 31 (79.5%) 17 (73.9%) 14 (87.5%) 0.432
ACEI/ARB 24 (61.5%) 14 (60.9%) 10 (62.5%) 0.918
Nitrates (no, %) 38 (97.4%) 22 (95.7%) 16 (100.0%) 1.000
Diuretics (no, %) 16 (41.0%) 6 (26.1%) 10 (62.5%) 0.023
CCU (hours) 48.0 (39.0–62.0) 47.0 (38.0–58.0) 52.5 (44.0–82.8) 0.123
  1. Data are data are presented as mean ± SD, median (interquartile ranges), or number (%)
  2. STEMI ST-segment elevation myocardial infarction, BMI body mass index, HP hypertension, DM diabetes mellitus, DES drug eluting stents, LAD left anterior descending coronary artery, LCC left circumflex coronary artery, RCA right coronary artery, LVIDD left ventricular diastolic diameter, LVEF left ventricular ejection fraction, ACEI angiotensin converting enzyme inhibitors, ARB angiotensin receptor blocker, CCU coronary heart disease care unit
  3. *P < 0.05 comparing with ST-segment resolution ≥ 40% group